Baorui
EN
Product Center
BSA Detection Kit (Enzyme-Linked Immunosorbent Assay)

BSA Detection Kit (Enzyme-Linked Immunosorbent Assay)

  • Item Number:BP-QP-B010-96
  • Product Overview
  • Experimental data

Cell culture methods are widely adopted in the production processes of fields such as vaccines, cell and gene therapy (CGT). Cell culture media usually contain fetal bovine serum, and bovine serum albumin (BSA) is one of its main components, providing the key nutrients required for cell growth. BSA is an exogenous protein. Once it enters the human body, it may trigger immune responses and allergic reactions. Therefore, in the production process and release testing of biological products, the pharmacopoeias and ICH of various countries strictly control the BSA residues in vaccines and other biological products.
The 2025 edition of the Chinese Pharmacopoeia (Part III) clearly stipulates that in all vaccine products, the residue of BSA shall not exceed 50 ng/mL or 50 ng per dose (except for inactivated hepatitis A vaccines). The United States Pharmacopeia stipulates that the residue limit of BSA in biological products is 50 ng per dose or 500 ppm. The European Pharmacopoeia requires that the residue of BSA be controlled between 0.1 and 1.0μg per dose.
This product uses the ELISA double antibody sandwich method to determine the BSA content in the sample. Anti-bsa antibody is coated on the solid-phase carrier microplate, and the standard or sample to be tested is added. The BSA detection antibody is formed to create an antibody-antigen-detection antibody complex. The content of BSA in the sample to be tested is quantitatively detected by color development. This series of reagent kits has undergone comprehensive methodological validation in accordance with relevant regulations, guidelines and other document requirements, and can provide performance validation reports.


012025121915554150.png
012025121915560063.png

012025121915552832.pngForQuantitative detection of variousrawThe content of BSA in intermediate products, semi-finished products and finished products of physical preparations (such as vaccine drugs, cell therapy, stem cells and tissue engineering products, etc.) can be used for monitoringrawResidual BSA during the production process and product release.


Contact us

0756-8699969

Address: No. 88, Shuian 1st Road, Nanping Science and Technology Park, Xiangzhou District, Zhuhai City, Guangdong Province

Email: marketing@biori.com

/web/images/299Kt/49a77651ec26d3e40dfb15c4d49f3c1648d3e7d7.png 

Wechat official account

 

Product consultation

 

Join us

 

Video Account

Website navigation

About Baorui         Corporate culture         Development history

Honors and qualifications         Product Center         Company News

Industry News         Employee Profile         Download Center

Contact us       


Site mapCopyright @2026 Zhuhai Baorui Biotechnology Co., LTDICP No. 19103206 of Guangdong Province